Guest Editorial by Nora Volkow - Advancing Reduction of Drug Use as an Endpoint in Addiction Treatment Trials

For many people trying to recover from a substance use disorder, perhaps for the majority, abstinence may be the most appropriate treatment objective. But complete abstinence is sometimes not achievable, even in the long-term, and there is a need for new treatment approaches that recognize the clinical value of reduced use.

The association between buprenorphine doses above 16 milligrams and treatment retention

This guideline was developed to help clinicians determine when the risks of continued BZD prescribing outweigh the benefits for a given patient and how to safely taper the medication when indicated. Existing guidelines generally recommend limiting duration of BZD use to 2-4 weeks (except for limited conditions such as severe treatment-resistant generalized anxiety disorder, complex seizure disorders, spasticity, and sleep disorders involving abnormal movements). However, long-term BZD prescribing remains prevalent.

Guest Editorial: New Clinical Practice Guideline - Benzodiazepine Tapering

Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality

Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders

Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl

Beyond Buprenorphine in the ED: Leveraging Lessons From 10 Years of Implementation

The opioid toxicity crisis remains an urgent public health priority across the US and Canada. Since the seminal randomized controlled trial published in 2015 found that buprenorphine initiation in the emergency department (ED) was superior compared with referral to treatment alone, buprenorphine initiation in the ED has been hailed as an important mechanism for addressing the overdose crisis.